Beraprost modified release, in addition to treprostinil, is in clinical development for the oral treatment of pulmonary arterial hypertension (PAH), a rare condition causing high blood pressure in the lungs. PAH can worsen over time and cause several problems including heart failure and blood clots. In PAH, the arteries in the lungs become thickened and stiff meaning the arteries cannot stretch as well to allow blood to flow through. This makes it harder for the heart to bump blood through the arteries leading to high blood pressure and weakening of the heart.
Beraprost modified release works by mimicking a naturally available substance in the body called prostacyclin which relaxes and widens the blood vessels and prevents the formation of blood clots. It is expected that beraprost modified release will relax and widen the blood vessels in the lungs, lowering blood pressure and therefore improving symptoms of PAH. This formulation of beraprost releases the drug over several hours, which reduces the frequency of administration, making this treatment more convenient to take. If licensed, beraprost modified release will offer an additional treatment option for patients with PAH in addition to treprostinil targeted therapy.
Dapagliflozin blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2). As blood is filtered by the kidneys, SGLT2 stops glucose in the bloodstream from being passed out into the urine. By blocking the action of SGLT2, dapagliflozin causes the kidney to pass out more glucose in the urine, thereby reducing the levels of glucose in the blood. Blood vessels can be damaged by the effects of high blood glucose levels and this can in turn cause damage to organs, such as the heart. Dapagliflozin may also increase the removal of fluid between tissue cells, contributing to reduced congestion with minimal impact on blood volume. If licensed, dapagliflozin may provide a treatment option for people with HFrEF who currently have limited therapies available.